The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...

CORAL SPRINGS, Fla., Jan. 12, 2026 /PRNewswire/ -- Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today announced that the U.S. Food and ...

Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...

This post was co-authored by Abigail Ramos and Robert T. Muller, Ph.D. With the development of new neuro-technology and emerging research on the function of the brain, the treatment of mental illness ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...

Magnus Medical, Inc., the company behind SAINT®, the first and only FDA-cleared, rapid-remission therapy for Major Depressive Disorder (MDD), today announced that the Centers for Medicare & Medicaid ...

With its expansion into St. Louis, Restore Brain continues its mission to broaden access to advanced psychiatric treatments ...

The International Neuromodulation Society (INS) journal Neuromodulation: Technology at the Neural Interface is publishing expert, evidence-based guidance on the safe and efficient use of ...

PARK CITY, Utah--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System, a patient-centric solution for urge urinary ...